Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its participation in three upcoming conferences. The company's senior leadership will be presenting at:
1. Wells Fargo Healthcare Conference in Boston on September 4, 2024, at 3:45 p.m. ET
2. Baird Global Healthcare Conference in New York on September 10, 2024, at 2:35 p.m. ET
3. H.C. Wainwright Global Investment Conference in New York on September 11, 2024, at 11:00 a.m. ET
Live and archived webcasts of these presentations will be accessible on the Iovance website at https://ir.iovance.com/news-events/events-presentations.
Iovance Biotherapeutics (NASDAQ: IOVA), una società biotecnologica specializzata in terapie innovative con linfociti infiltranti tumorali (TIL) per pazienti affetti da cancro, ha annunciato la sua partecipazione a tre conferenze imminenti. I dirigenti senior dell'azienda presenteranno:
1. Wells Fargo Healthcare Conference a Boston il 4 settembre 2024, alle 15:45 ET
2. Baird Global Healthcare Conference a New York il 10 settembre 2024, alle 14:35 ET
3. H.C. Wainwright Global Investment Conference a New York l'11 settembre 2024, alle 11:00 ET
Le dirette e le registrazioni di queste presentazioni saranno disponibili sul sito web di Iovance all'indirizzo https://ir.iovance.com/news-events/events-presentations.
Iovance Biotherapeutics (NASDAQ: IOVA), una empresa biotecnológica especializada en nuevas terapias con linfocitos infiltrantes tumorales (TIL) para pacientes con cáncer, ha anunciado su participación en tres conferencias próximas. El equipo directivo senior de la compañía presentará en:
1. Wells Fargo Healthcare Conference en Boston el 4 de septiembre de 2024, a las 3:45 p.m. ET
2. Baird Global Healthcare Conference en Nueva York el 10 de septiembre de 2024, a las 2:35 p.m. ET
3. H.C. Wainwright Global Investment Conference en Nueva York el 11 de septiembre de 2024, a las 11:00 a.m. ET
Las transmisiones en vivo y grabadas de estas presentaciones estarán accesibles en el sitio web de Iovance en https://ir.iovance.com/news-events/events-presentations.
Iovance Biotherapeutics (NASDAQ: IOVA)는 암 환자를 위한 신규 다클론 종양 침윤 림프구(TIL) 치료법을 전문으로 하는 생명공학 회사로, 다가오는 세 개의 컨퍼런스에 참여할 예정임을 발표했습니다. 회사의 고위 경영진이 발표할 예정입니다:
1. 웰스 파고 헬스케어 컨퍼런스 - 2024년 9월 4일 보스턴에서 오후 3시 45분 ET
2. 베어드 글로벌 헬스케어 컨퍼런스 - 2024년 9월 10일 뉴욕에서 오후 2시 35분 ET
3. H.C. 웨인라이트 글로벌 투자 컨퍼런스 - 2024년 9월 11일 뉴욕에서 오전 11시 ET
이 발표의 생중계 및 녹화된 웹캐스트는 Iovance 웹사이트에서 확인할 수 있습니다: https://ir.iovance.com/news-events/events-presentations.
Iovance Biotherapeutics (NASDAQ: IOVA), une entreprise biopharmaceutique spécialisée dans de nouvelles thérapies par lymphocytes tumoraux polyclonaux (TIL) pour les patients atteints de cancer, a annoncé sa participation à trois conférences à venir. La direction de l'entreprise présentera :
1. Wells Fargo Healthcare Conference à Boston le 4 septembre 2024, à 15h45 ET
2. Baird Global Healthcare Conference à New York le 10 septembre 2024, à 14h35 ET
3. H.C. Wainwright Global Investment Conference à New York le 11 septembre 2024, à 11h00 ET
Les diffusions en direct et les enregistrements de ces présentations seront accessibles sur le site web d'Iovance à l'adresse https://ir.iovance.com/news-events/events-presentations.
Iovance Biotherapeutics (NASDAQ: IOVA), ein Biotech-Unternehmen, das sich auf neuartige polyklonale tumorinfiltrierende Lymphozytentherapien (TIL) für Krebspatienten spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Konferenzen angekündigt. Die Unternehmensleitung wird folgende Präsentationen halten:
1. Wells Fargo Healthcare Conference in Boston am 4. September 2024 um 15:45 Uhr ET
2. Baird Global Healthcare Conference in New York am 10. September 2024 um 14:35 Uhr ET
3. H.C. Wainwright Global Investment Conference in New York am 11. September 2024 um 11:00 Uhr ET
Live- und archivierte Webcasts dieser Präsentationen sind auf der Website von Iovance unter https://ir.iovance.com/news-events/events-presentations verfügbar.
- None.
- None.
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
- Wells Fargo Healthcare Conference
Fireside Chat: September 4, 2024 at 3:45 p.m. ET
Boston, MA - Baird Global Healthcare Conference
Fireside Chat: September 10, 2024 at 2:35 p.m. ET
New York, NY - H.C. Wainwright Global Investment Conference
Presentation: September 11, 2024 at 11:00 a.m. ET
New York, NY
The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control.
FAQ
What conferences will Iovance Biotherapeutics (IOVA) attend in September 2024?
When is Iovance Biotherapeutics (IOVA) presenting at the Wells Fargo Healthcare Conference?
Where can I watch the webcasts of Iovance Biotherapeutics' (IOVA) conference presentations?